131.87 USD
-0.05 (-0.04%)
131.92 USD
+0.05 (+0.04%)
Taking everything into account, ITCI scores 5 out of 10 in our fundamental rating. ITCI was compared to 191 industry peers in the Pharmaceuticals industry. ITCI has a great financial health rating, but its profitability evaluates not so good. ITCI is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ITCI had negative earnings in the past year.
In the past year ITCI has reported a negative cash flow from operations.
ITCI had negative earnings in each of the past 5 years.
ITCI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ITCI (-5.46%) is better than 73.37% of its industry peers.
ITCI has a better Return On Equity (-6.50%) than 78.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.46% | ||
| ROE | -6.5% | ||
| ROIC | N/A |
ROA(3y)-19.53%
ROA(5y)-29.65%
ROE(3y)-23.06%
ROE(5y)-34.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ITCI (91.63%) is better than 94.97% of its industry peers.
ITCI's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ITCI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ITCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ITCI has more shares outstanding
ITCI has more shares outstanding than it did 5 years ago.
ITCI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ITCI has an Altman-Z score of 38.03. This indicates that ITCI is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 38.03, ITCI belongs to the best of the industry, outperforming 97.49% of the companies in the same industry.
ITCI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 38.03 |
ROIC/WACCN/A
WACC9.49%
2.3 Liquidity
ITCI has a Current Ratio of 6.36. This indicates that ITCI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.36, ITCI is in the better half of the industry, outperforming 76.38% of the companies in the same industry.
A Quick Ratio of 6.23 indicates that ITCI has no problem at all paying its short term obligations.
The Quick ratio of ITCI (6.23) is better than 76.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.36 | ||
| Quick Ratio | 6.23 |
3. Growth
3.1 Past
ITCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
Looking at the last year, ITCI shows a very strong growth in Revenue. The Revenue has grown by 46.61%.
Measured over the past years, ITCI shows a very strong growth in Revenue. The Revenue has been growing by 484.27% on average per year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
Revenue 1Y (TTM)46.61%
Revenue growth 3Y101.03%
Revenue growth 5Y484.27%
Sales Q2Q%50.81%
3.2 Future
ITCI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 87.04% yearly.
ITCI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.51% yearly.
EPS Next Y127.35%
EPS Next 2Y174.17%
EPS Next 3Y140.69%
EPS Next 5Y87.04%
Revenue Next Year40.33%
Revenue Next 2Y50.81%
Revenue Next 3Y47.62%
Revenue Next 5Y37.51%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ITCI. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 660.59, ITCI can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ITCI is valued a bit cheaper than the industry average as 73.37% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ITCI to the average of the S&P500 Index (23.83), we can say ITCI is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 660.59 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ITCI does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as ITCI's earnings are expected to grow with 140.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y174.17%
EPS Next 3Y140.69%
5. Dividend
5.1 Amount
ITCI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
131.87
-0.05 (-0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners94.75%
Inst Owner Change-26.28%
Ins Owners0.23%
Ins Owner Change0%
Market Cap14.05B
Revenue(TTM)680.85M
Net Income(TTM)-74.68M
Analysts72.22
Price Target133.21 (1.02%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.8%
Min EPS beat(2)-40.63%
Max EPS beat(2)-24.97%
EPS beat(4)2
Avg EPS beat(4)0.62%
Min EPS beat(4)-40.63%
Max EPS beat(4)50.59%
EPS beat(8)6
Avg EPS beat(8)17.95%
EPS beat(12)9
Avg EPS beat(12)16.57%
EPS beat(16)10
Avg EPS beat(16)13.07%
Revenue beat(2)1
Avg Revenue beat(2)0.38%
Min Revenue beat(2)-0.24%
Max Revenue beat(2)1%
Revenue beat(4)3
Avg Revenue beat(4)0.36%
Min Revenue beat(4)-0.24%
Max Revenue beat(4)1%
Revenue beat(8)6
Avg Revenue beat(8)0.51%
Revenue beat(12)9
Avg Revenue beat(12)1.93%
Revenue beat(16)11
Avg Revenue beat(16)1.25%
PT rev (1m)-0.1%
PT rev (3m)26.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.86%
EPS NY rev (1m)-30.48%
EPS NY rev (3m)-47.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.15%
Revenue NY rev (1m)0.91%
Revenue NY rev (3m)1.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 660.59 | ||
| P/S | 20.63 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 12.23 | ||
| P/tB | 12.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.73
EYN/A
EPS(NY)0.2
Fwd EY0.15%
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS6.39
BVpS10.78
TBVpS10.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.46% | ||
| ROE | -6.5% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.63% | ||
| FCFM | N/A |
ROA(3y)-19.53%
ROA(5y)-29.65%
ROE(3y)-23.06%
ROE(5y)-34.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5YN/A
F-Score4
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 63.39% | ||
| Cap/Sales | 0.05% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.36 | ||
| Quick Ratio | 6.23 | ||
| Altman-Z | 38.03 |
F-Score4
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)77.5%
Cap/Depr(5y)69.14%
Cap/Sales(3y)0.14%
Cap/Sales(5y)0.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
EPS Next Y127.35%
EPS Next 2Y174.17%
EPS Next 3Y140.69%
EPS Next 5Y87.04%
Revenue 1Y (TTM)46.61%
Revenue growth 3Y101.03%
Revenue growth 5Y484.27%
Sales Q2Q%50.81%
Revenue Next Year40.33%
Revenue Next 2Y50.81%
Revenue Next 3Y47.62%
Revenue Next 5Y37.51%
EBIT growth 1Y26.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year126.61%
EBIT Next 3Y133.69%
EBIT Next 5Y90.06%
FCF growth 1Y40.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.08%
OCF growth 3YN/A
OCF growth 5YN/A
INTRA-CELLULAR THERAPIES INC / ITCI FAQ
Can you provide the ChartMill fundamental rating for INTRA-CELLULAR THERAPIES INC?
ChartMill assigns a fundamental rating of 5 / 10 to ITCI.
Can you provide the valuation status for INTRA-CELLULAR THERAPIES INC?
ChartMill assigns a valuation rating of 1 / 10 to INTRA-CELLULAR THERAPIES INC (ITCI). This can be considered as Overvalued.
Can you provide the profitability details for INTRA-CELLULAR THERAPIES INC?
INTRA-CELLULAR THERAPIES INC (ITCI) has a profitability rating of 2 / 10.
How financially healthy is INTRA-CELLULAR THERAPIES INC?
The financial health rating of INTRA-CELLULAR THERAPIES INC (ITCI) is 8 / 10.